AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34293738
Drug: Ferric citrate
RxNorm normalized name: Ferric Citrate
DrugBank: Ferric sodium citrate (DB13771)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric citrate (FC) 1 tablet (1-g equivalent to 210 mg ferric iron) TID (3 g/day)
Trial: 34293738
Drug: Ferric citrate
RxNorm normalized name: Ferric Citrate
DrugBank: Ferric sodium citrate (DB13771)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric citrate (FC) 2 tablets BID (4 g/day)
Trial: 34605026
Drug: β‐OHB supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β‐OHB supplementation (30 mL or 12 g, thrice-daily for 14 days)
Trial: 35551683
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg, q.d. for 4 weeks
Trial: 36255254
Drug: 0.05% Dapivirine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% Dapivirine gel administered rectally using an applicator (2.5 g)
Trial: 36255254
Drug: Dapivirine gel
RxNorm normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapivirine gel self-administered as lubricant (up to 10 g)
Trial: 36361215
Drug: Integrative cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative cognitive function improvement program administered to CN and MCI groups for six weeks.
Trial: 34180278
Drug: CTFA-GRT (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTFA-GRT (group reminiscence therapy based on Chinese traditional festival activities)
Trial: 34918965
Drug: Restrictive Fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive Fluid Therapy (Control)
Trial: 34918965
Drug: Both GDFT
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both GDFT and Restrictive Fluid Therapy
Trial: 32268439
Drug: Pre-emptive administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-emptive administration of ibuprofen or paracetamol
Trial: 33074393
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity laser therapy (HILT) + exercise therapy (ET)
Trial: 33074393
Drug: Placebo laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo laser (PL) + exercise therapy (ET)
Trial: 32187789
Drug: biomedically focused
RxNorm normalized name: hypromellose
DrugBank: Hypromellose (DB11075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: biomedically focused education and exercise therapy
Trial: 35359035
Drug: 4% mangosteen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% mangosteen gel
Trial: 35102171
Drug: SAMiRNA-AR68 (AR68)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAMiRNA-AR68 (AR68) at a low dose of 0.5 mg/ml applied three times per week for 24 weeks
Trial: 35102171
Drug: SAMiRNA-AR68 (AR68)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAMiRNA-AR68 (AR68) at a high dose of 5 mg/ml given once per week for 24 weeks
Trial: 33737199
Drug: Sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine (SL-BUP)
Trial: 33737199
Drug: 7-day extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day extended-release injectable buprenorphine (CAM2038, XR-BUP)
Trial: 33908636
Drug: Vedolizumab 300
RxNorm normalized name: vedolizumab 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab 300 mg intravenously every 4 weeks (continuously treated)
Trial: 33908636
Drug: Vedolizumab 300
RxNorm normalized name: vedolizumab 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab 300 mg intravenously every 4 weeks (re-treated after treatment interruption)
Trial: 33908636
Drug: Placebo maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo maintenance (during treatment interruption)
Trial: 34171279
Drug: 7+3 (cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7+3 (cytarabine and daunorubicin chemotherapy)
Trial: 32577871
Drug: EMR with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMR with the application of 0.3 ml of N-butyl-2-cyanoacrylate + methacryloxysulfolane—Glubran 2®
Trial: 32367748
Drug: Baihe Gujin
RxNorm normalized name: Yujin (Curcuma Longa)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baihe Gujin decoction combined with anti-tuberculosis therapy
Trial: 32367748
Drug: Anti-tuberculosis treatment
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-tuberculosis treatment
Trial: 33165125
Drug: Time‐varying reactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time‐varying reactive urine toxicology results for stimulants
Trial: 33951415
Drug: Alirocumab (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (150 mg biweekly subcutaneous)
Trial: 35978289
Drug: Multi-faceted exercise
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-faceted exercise intervention (thrice weekly aerobic and progressive resistance training, reducing sedentary time by 30 min)
Trial: 35818509
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day aspirin
Trial: 33334939
Drug: Low-dose theophylline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose theophylline 100 mg twice daily plus low-dose oral prednisone 5 mg once daily
Trial: 33334939
Drug: Low-dose theophylline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose theophylline 100 mg twice daily plus placebo
Trial: 33584074
Drug: Quiklean® (32-tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quiklean® (32-tablet sodium phosphate)
Trial: 33584074
Drug: Klean‐Prep/Dulcolax® (2-L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Klean‐Prep/Dulcolax® (2-L polyethylene glycol/bisacodyl)
Trial: 32250536
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec (degludec)
Trial: 34647404
Drug: Tirzepatide 5
RxNorm normalized name: tirzepatide 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide 5 mg (weeks 1-8)
Trial: 34647404
Drug: Tirzepatide 10
RxNorm normalized name: tirzepatide 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide 10 mg (2.5 mg weeks 1-2; 5 mg weeks 3-4; 10 mg weeks 5-8)
Trial: 34647404
Drug: Tirzepatide 15
RxNorm normalized name: tirzepatide 15 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide 15 mg (5 mg weeks 1-2; 10 mg weeks 3-6; 15 mg weeks 7-8)
Trial: 32180266
Drug: Wiping twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wiping twice with pressure ≥40 mmHg
Trial: 34059080
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of umbilical cord-derived Wharton's jelly (WJ)
Trial: 35948970
Drug: We Can
RxNorm normalized name: CAN-106
DrugBank: CAN-106 (DB18389)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We Can Quit intervention with free nicotine replacement therapy (NRT)
Trial: 32446306
Drug: Fenofibrate treatment
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate treatment group (n = 28)
Trial: 34109778
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 buccal spray (2000 U, n=30) for six weeks
Trial: 34109778
Drug: Oral drops
RxNorm normalized name: Oral Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral drops (2000 U, n=30) for six weeks
Trial: 34109778
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose (300,000 U, n=30)
Trial: 33147541
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg nano-curcumin for two months
Trial: 36174766
Drug: F2 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F2 group (etch-mineralizing solution with 10 mg/ml sodium fluoride)
Trial: 36174766
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (35% phosphoric acid gel treatment)
Trial: 35500846
Drug: Micro-infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-infusion pump at 2 ml/h without accompanying fluid (Observation group)
Trial: 35500846
Drug: Micro-infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-infusion pump at 2 ml/h with normal saline (Control group)
Trial: 34055118
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health status measured by OHI-S
Trial: 32053557
Drug: Low tidal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal volume ventilation (6.5 ± 1.8 ml/kg predicted body weight)
Trial: 32053557
Drug: Intermediate tidal
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate tidal volume ventilation (9.5 ± 1.6 ml/kg predicted body weight)
Trial: 35491787
Drug: PBM therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBM therapy (real light therapy)
Trial: 35786297
Drug: Chiropractic spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiropractic spinal manipulative therapy and exercise
Trial: 36309744
Drug: Electronic pillbox
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic pillbox intervention with pre-filled weekly blister pack medication trays, alarms, detection of pill removal, alerts to patients or caregivers, adherence reports, and pharmacist outreach for missed doses.
Trial: 34474731
Drug: Metoprolol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (15 mg daily for 3 days)
Trial: 33734782
Drug: Cognitive-behavioral substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral substance use treatment (standard)
Trial: 33734782
Drug: Cognitive-behavioral substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral substance use treatment (culturally accommodated)
Trial: 34023938
Drug: Wild blueberry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wild blueberry (WBB) drink intervention (766 mg total polyphenols; 253 mg anthocyanins; equivalent to 240 g fresh blueberries per day)
Trial: 32739320
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose to the posterior prostate and surrounding regions in RADAR and RT01 patients
Trial: 32739320
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose to the seminal vesicle region in RADAR intermediate-risk patients
Trial: 32641470
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium 220 mg
Trial: 36088627
Drug: Intralesional measles,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional measles, mumps, and rubella (MMR) vaccine
Trial: 34097368
Drug: Rituximab (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1000 mg on days 1, 15, 168, and 182)
Trial: 32096120
Drug: High cumulative
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High cumulative propofol dose (1316 mg/kg)
Trial: 34340096
Drug: Shangliao point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shangliao point injection combined with epidural analgesia
Trial: 34340096
Drug: Shangliao point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shangliao point injection
Trial: 34340096
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia and saline injection
Trial: 32593779
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin (150 mg/day)
Trial: 32926259
Drug: Transinguinal preperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transinguinal preperitoneal repair with modified Kugel patch (MK)
Trial: 32641101
Drug: Bortezomib (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (up to 3 cycles, each 21 days with 4 subcutaneous applications)
Trial: 32641101
Drug: Placebo (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (up to 3 cycles, each 21 days with 4 subcutaneous applications)
Trial: 36222880
Drug: 10-mg dose
RxNorm normalized name: diazepam
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-mg dose of amiloride
Trial: 34922807
Drug: Mobilization Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobilization Group (MG) - five days of standard gait training and early ambulation
Trial: 35605176
Drug: Venetoclax-rituximab (VenR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax-rituximab (VenR) with undetectable minimal residual disease (uMRD) at end of treatment (EOT)
Trial: 36241511
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid administered before surgical incision (pre-induction groups)
Trial: 36241511
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid administered just before tourniquet release (pre-release groups)
Trial: 36241511
Drug: Single-dose groups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose groups (tranexamic acid administered once)
Trial: 36241511
Drug: Double-dose groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose groups (tranexamic acid administered twice)
Trial: 36241511
Drug: Double-dose groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose groups
Trial: 37682887
Drug: Antibiotic paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic paste (CTZ)
Trial: 33991032
Drug: Carboxytherapy (intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboxytherapy (intradermal injection of 5 cc carbon-dioxide gas once weekly for 6 weeks)
Trial: 33991032
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) therapy (intradermal injection of PRP every 2 weeks for three times)
Trial: 32199156
Drug: Alcohol dose
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol dose of 0.65 g/kg
Trial: 32529495
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) treatment
Trial: 32466879
Drug: Mavacamten (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavacamten (200 ng/ml)
Trial: 32466879
Drug: Mavacamten (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavacamten (500 ng/ml)
Trial: 32920767
Drug: 40 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 Gy equivalent dose
Trial: 32920767
Drug: 50 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 Gy equivalent dose
Trial: 32629757
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (6000 IU daily for eight weeks)
Trial: 35093047
Drug: Guided internet-
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided internet- and mobile-based cognitive behavioral therapy (iCBT) youthCOACHCD (IG, n=15)
Trial: 35093047
Drug: Guided internet-
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided internet- and mobile-based cognitive behavioral therapy (iCBT) youthCOACHCD (IG)
Trial: 35597965
Drug: Multidisciplinary rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary rehabilitation program combining multimodal exercises with psychologist-led cognitive-behavioral therapy sessions
Trial: 34812096
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (MFR and NAFL)
Trial: 33607008
Drug: lumacaftor–ivacaftor therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lumacaftor–ivacaftor therapy
Trial: 35436611
Drug: SpikoGen® vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SpikoGen® vaccine (25 μg, two doses, 3 weeks apart)
Trial: 32978182
Drug: Mirror Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror Therapy (MT) combined with task-oriented training
Trial: 36252934
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg lutein + 2 mg zeaxanthin
Trial: 32363968
Drug: Intrauterine infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrauterine infusion of 0.5 ml of platelet-rich plasma (PRP) 48 hours before embryo transfer
Trial: 32938470
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) starting from 5 mg per week for the first 2 weeks, increasing to 10 mg per week for the second 2 weeks, and 15 mg per week for the remaining period if tolerated
Trial: 34614204
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg ramosetron with IV-PCA
Trial: 34614204
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dexamethasone before induction of anesthesia with IV-PCA
Trial: 32925205
Drug: Tumor-treating fields
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor-treating fields therapy
Trial: 35047630
Drug: Ulinastatin combined
RxNorm normalized name: ulinastatin
DrugBank: Ulinastatin (DB12038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin combined with Xingnaojing injection
Trial: 36409064
Drug: CTN-1 V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CTN-1 V human rabies vaccine (Vero cells) administered via the Essen Regimen (single dose on days 0, 3, 7, 14, and 28)
Trial: 36409064
Drug: CTN-1 V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CTN-1 V human rabies vaccine (Vero cells)
Trial: 33586072
Drug: Conventional chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemoradiation therapy after induction chemotherapy
Trial: 33586072
Drug: Combinations of
RxNorm normalized name: Combinations of vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combinations of local ablation and immunotherapy
Trial: 36105647
Drug: Natural control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural control (CK) treatment
Trial: 35363600
Drug: Baseline FVC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline FVC bronchodilator responsiveness
Trial: 35363600
Drug: Interactions between
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactions between lung function reduction and treatment assignment
Trial: 35363600
Drug: Baseline bronchodilator
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline bronchodilator responsiveness measures
Trial: 33529588
Drug: 0.25% topical
RxNorm normalized name: Remyda, 0.25% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% topical ocular reproxalap
Trial: 32408117
Drug: Saffron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron supplementation (100 mg/day)
Trial: 32876858
Drug: Qingfei Yihuo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingfei Yihuo Capsules (QYCs)
Trial: 33100187
Drug: Group Cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive Behavioral Therapy (CBT) for 12 weeks
Trial: 35972345
Drug: CIRAS model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIRAS model (developed using variables: ascites discomfort score, plasma sodium levels, and a composite of ascites accumulation and diuretic treatment)